In one of the first studies to evaluate taxanes versus anthracyclines in the neoadjuvant setting, no added clinical benefit in either overall survival (OS) or disease-free survival (DFS) for the simultaneous administration of doxorubicin and docetaxel compared to doxorubicin and cyclophosphamide was observed during a median of 119 months of follow-up. Importantly, this does not exclude the possibility of the occurrence of a smaller benefit than the study was powered to detect, according to researchers.
In this phase 3, multicentre, randomised trial involving 25 centres in the United Kingdom, Ireland, and Belgium, the long-term outcome of women with primary or locally advanced breast cancer who were randomised to receive either doxorubicin and cyclophosphamide (n=181) or doxorubicin and docetaxel (n=182) as primary chemotherapy were compared . The maximum number of cycles was 6 cycles of either doxorubicin (60 mg/m2) + cyclophosphamide (600 mg/m2) admini...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Clinical benefit over trastuzumab for margetuximab in HER2 breast cancer Next Article
Circulating tumour DNA may help predict recurrence in patients with early triple-negative breast cancer »